 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
1 News |  |
- | BT1718 / Bicycle Therap
Trial completion, Trial completion date, Trial primary completion date, Metastases: CRUKD/17/009: BT1718 in Patients With Advanced Solid Tumours. (clinicaltrials.gov) - Feb 7, 2024
P1/2, N=72, Completed, Sponsor: Cancer Research UK
Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Nov 2023 | Trial primary completion date: Dec 2024 --> Nov 2023
- | BT1718 / Bicycle Therap
Enrollment closed, Enrollment change, Metastases: CRUKD/17/009: BT1718 in Patients With Advanced Solid Tumours. (clinicaltrials.gov) - Mar 21, 2023
P1/2, N=72, Active, not recruiting, Sponsor: Cancer Research UK
Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Nov 2023 | Trial primary completion date: Dec 2024 --> Nov 2023 Recruiting --> Active, not recruiting | N=130 --> 72
- | BT1718 / Bicycle Therap
Trial completion date, Trial primary completion date, Metastases: CRUKD/17/009: BT1718 in Patients With Advanced Solid Tumours. (clinicaltrials.gov) - Aug 17, 2022
P1/2, N=130, Recruiting, Sponsor: Cancer Research UK
Recruiting --> Active, not recruiting | N=130 --> 72 Trial completion date: Mar 2022 --> Dec 2024 | Trial primary completion date: Mar 2022 --> Dec 2024
- || BT1718 / Bicycle Therap
P1 data, Journal: Development of a LC-MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I study. (Pubmed Central) - Dec 1, 2021
The method was fully validated over a linear range of 200-50,000 ng/ml BT1718, with overall precision ≤10% and accuracy 89-102%. A novel method for quantifying DM1 yielded from BT1718 has been validated and is now being utilized clinically.
- ||||| BT1718 / Bicycle Therap
Clinical: It takes two to tango: targeting tumour and stroma. Presented early clinical trial data on FIH study of novel anticancer agent BT1718. Thank you to patients and clinical trials teams. #ENASymp20 @ICR_London @royalmarsdenNHS @ECMC_UK @CR_UK @NIHRresearch (Twitter) - Oct 25, 2020
- BT1718 / Bicycle Therap
[VIRTUAL] BT1718 (Channel 2) - Aug 4, 2020 - Abstract #AACRNCIEORTC2020AACR_NCI_EORTC_34;
A novel method for quantifying DM1 yielded from BT1718 has been validated and is now being utilized clinically. Abstract not received.
- BT1718 / Bicycle Therap
Integrative surfaceome profiling identifies MMP14, MRC2 and CD276 as candidate immunotherapeutic target in osteosarcomas (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2544;
Our current findings have not been previously reported in OS. The results might warrant further development of ADC and CAR-T cell therapy for osteosarcomas against these targets.
- || BT1718 / Bicycle Therap
@Physiomics #PYC partner with BT1718 hopefully @Bicycle_tx can pass on good vibes to @Genentech (Twitter) - Feb 25, 2020
- ||| BT1718 / Bicycle Therap
$BCYC #ESMO19 BT1718 poster, via Natalie Cook (Twitter) - Sep 28, 2019
- BT1718 / Bicycle Therap
MT1-MMP Immunohistochemistry (IHC) analysis of tumor microarrays (TMAs) using a novel scoring system guides patient selection for BT1718 expansion cohorts (Board 47: Level 2 - Hall D) - Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_81;
The results might warrant further development of ADC and CAR-T cell therapy for osteosarcomas against these targets. Based on these analyses; squamous lung, squamous esophageal, and an all comers high MT1-MMP basket were selected (using a TM cut-off of at least H-score ≥100) as the three proposed BT1718 expansion cohorts.
- BT1718 / Bicycle Therap
Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1487;
P1/2
Current plasma and tumor PK data are consistent with proposed preclinical mechanism of tumor targeted toxin delivery. Clinical trial identification: NCT03486730.
- | BT1718 / Bicycle Therap
New P1/2 trial, Metastases: CRUKD/17/009: BT1718 in Patients With Advanced Solid Tumours. (clinicaltrials.gov) - Jul 15, 2018
P1/2, N=120, Recruiting, Sponsor: Cancer Research UK